试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
Evaluating the Efficacy and Safety of Metformin in Vitiligo
编号:NCT05607316登记状态:入组前撤回企业 / 申办者:University of Massachusetts, Worcester
药物 / 成分:Metformin Hydrochloride
登记的停止原因(原文):Unable to secure funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
编号:NCT05778877登记状态:入组前撤回企业 / 申办者:Selecta Biosciences, Inc.
药物 / 成分:SEL-302
登记的停止原因(原文):Decided by sponsor
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
Detection of Coronary Stenosis With Intravenous Microbubbles
编号:NCT00580580登记状态:入组前撤回企业 / 申办者:University of Nebraska
药物 / 成分:Optison、Definity、PESDA
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
编号:NCT00792662登记状态:入组前撤回企业 / 申办者:University of Nebraska
药物 / 成分:Methylphenidate、Placebo
登记的停止原因(原文):No Subjects enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty
编号:NCT06333522登记状态:入组前撤回企业 / 申办者:NYU Langone Health
药物 / 成分:Losartan
登记的停止原因(原文):Study team unable to identify method for approval of the medication as standard of care and compounded.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-20
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
编号:NCT03433833登记状态:入组前撤回企业 / 申办者:University of Illinois Chicago
药物 / 成分:Digoxin
登记的停止原因(原文):Study Not Funded
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-20
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
编号:NCT04488159登记状态:入组前撤回企业 / 申办者:Johannes Laengle, MD, PhD
药物 / 成分:Capecitabine、Oxaliplatin、Fluorouracil、Leucovorin
登记的停止原因(原文):Lack of funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-20
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
编号:NCT06078202登记状态:入组前撤回企业 / 申办者:AbbVie
药物 / 成分:ABBV-903
登记的停止原因(原文):Strategic considerations
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
编号:NCT06099418登记状态:入组前撤回企业 / 申办者:Nykode Therapeutics ASA
药物 / 成分:VB10.16、Atezolizumab Injection [Tecentriq]、Placebo
登记的停止原因(原文):Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care in the recurrent and metastatic cervical cancer setting.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Lithium Versus Paroxetine in Major Depression
编号:NCT01416220登记状态:入组前撤回企业 / 申办者:Nova Scotia Health Authority
药物 / 成分:Lithium、Paroxetine
登记的停止原因(原文):recruitment difficulties
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS
编号:NCT03365414登记状态:入组前撤回企业 / 申办者:University of Alberta
药物 / 成分:Albumin (Human) 5%, USP、Normal Saline 0.9% Infusion Solution Bag
登记的停止原因(原文):Withdrawal of support of product for trial
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Creatine Monohydrate Use for Preventing Altitude Induced Depression
编号:NCT03433651登记状态:入组前撤回企业 / 申办者:Mike O'Callaghan Military Hospital
药物 / 成分:Creatine monohydrate、Placebo
登记的停止原因(原文):Unable to locate grant funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients.
编号:NCT03747562登记状态:入组前撤回企业 / 申办者:University Hospital, Ghent
药物 / 成分:Gabapentin、Placebo
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Cannabidiol for Alcohol Use Disorder
编号:NCT03904849登记状态:入组前撤回企业 / 申办者:Medical University of South Carolina
药物 / 成分:Cannabidiol、Placebo
登记的停止原因(原文):This study was intended to produce pilot data for a center grant component that will no longer be conducted.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Spironolactone for Hidradenitis Suppurativa
编号:NCT04100083登记状态:入组前撤回企业 / 申办者:Medical University of South Carolina
药物 / 成分:Spironolactone 50 MG、Spironolactone 100mg、Spironolactone 200 mg
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.
编号:NCT04181359登记状态:入组前撤回企业 / 申办者:University of Alberta
药物 / 成分:Nitric Oxide、Placebo
登记的停止原因(原文):Study was no longer feasible as designed.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy
编号:NCT04418024登记状态:入组前撤回企业 / 申办者:Eidos Therapeutics, a BridgeBio company
药物 / 成分:AG10、Placebo
登记的停止原因(原文):After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Validate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
编号:NCT04435704登记状态:入组前撤回企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Oxytocin
登记的停止原因(原文):Study was not initiated. No subjects enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Effects of Baclofen on Presynaptic Inhibition in Humans
编号:NCT04471714登记状态:入组前撤回企业 / 申办者:University of Alberta
药物 / 成分:Baclofen
登记的停止原因(原文):Study recruitment was halted due to restrictions and we have decided to not pursue it further.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
编号:NCT04580238登记状态:入组前撤回企业 / 申办者:University of Alberta
药物 / 成分:Botox 200 UNT Injection、Non Botox based Standard of Care Treatments for Headache/Migraine
登记的停止原因(原文):Logistical issues
查看官方原始记录 ↗